Latest News and Press Releases

Highlights Net service revenue of $592.2 million and $1,102.4 million for the three and nine months ended September 30, 2017, respectively.Combined Company adjusted net service revenue of $766.6...

RALEIGH, N.C., Oct. 19, 2017 (GLOBE NEWSWIRE) -- INC Research/inVentiv Health (Nasdaq:INCR), the only fully-integrated biopharmaceutical solutions organization combining a CRO and CCO (Contract...

RALEIGH, N.C., Oct. 10, 2017 (GLOBE NEWSWIRE) -- INC Research/inVentiv Health (Nasdaq:INCR), the only fully integrated biopharmaceutical solutions organization combining a CRO and CCO (Contract...

RALEIGH, N.C., Aug. 21, 2017 (GLOBE NEWSWIRE) -- INC Research/inVentiv Health (Nasdaq:INCR), the only fully-integrated biopharmaceutical solutions organization, today announced that Chief Financial...

Combination Creates the Only Fully Integrated Biopharmaceutical Solutions Organization with Combined Net Revenue of More Than $3 Billion Relaunch Under New Brand Planned for 2018 RALEIGH, N.C. and...

Highlights Book-to-bill ratio of 1.6x, 1.5x, and 1.4x for the three-, six-, and twelve-month periods ended June 30, 2017, respectively.Net new business awards of $423.8 million and $783.8 million for...

RALEIGH, N.C., July 05, 2017 (GLOBE NEWSWIRE) -- INC Research Holdings, Inc. (Nasdaq:INCR), a leading, global Phase I to IV contract research organization, today announced the launch of the...

RALEIGH, N.C., June 28, 2017 (GLOBE NEWSWIRE) -- INC Research Holdings, Inc. (Nasdaq:INCR), a leading, global Phase I to IV contract research organization (CRO), today announced the expansion and...

RALEIGH, N.C., June 14, 2017 (GLOBE NEWSWIRE) -- INC Research Holdings, Inc. (Nasdaq:INCR), a leading global Phase I to IV contract research organization, today announced an extensive presence at...

RALEIGH, N.C., April 20, 2017 (GLOBE NEWSWIRE) -- INC Research Holdings, Inc. (Nasdaq:INCR), a leading, global Phase I to IV contract research organization, will release its first quarter 2017...